Motexafin lutetium

Motexafin lutetium is a photosensitizer used in photodynamic therapy (PDT) for the treatment of various types of cancer. It is a synthetic porphyrin derivative that is activated by light to produce a form of oxygen that can kill nearby cells.

Mechanism of Action[edit | edit source]

Motexafin lutetium works by accumulating in cancer cells where it is activated by light to produce a form of oxygen known as singlet oxygen. This reactive oxygen species can cause damage to cellular components, leading to cell death. The light used to activate motexafin lutetium is typically in the red or near-infrared range, which can penetrate tissue to a depth of several centimeters.

Clinical Use[edit | edit source]

Motexafin lutetium has been studied for use in a variety of cancers, including prostate cancer, brain tumors, and head and neck cancer. It is typically administered intravenously and then activated by light delivered to the tumor site through fiber optic cables. The light activation step is typically performed during surgery or through a minimally invasive procedure.

Side Effects[edit | edit source]

Common side effects of motexafin lutetium include skin sensitivity to light, known as photosensitivity, and mild to moderate pain at the treatment site. Other potential side effects include nausea, vomiting, and fever.

Research[edit | edit source]

Research into the use of motexafin lutetium for cancer treatment is ongoing. Current studies are focused on optimizing the light delivery method, determining the optimal dose and timing of drug administration, and identifying which types of cancer are most responsive to treatment.